Precision Medicine Gaps Persist Amid Evidence and Access Challenges: Daryl Pritchard, PhD

Why It Matters

Without solid evidence and seamless decision support, payers hesitate to reimburse, slowing the rollout of therapies that could improve outcomes and reduce overall healthcare costs.

Key Takeaways

• Fragmented coverage and frameworks limit precision‑medicine rollout
• Lack of robust outcomes data stalls payer reimbursement decisions
• Integrating decision‑support tools into EHRs bridges treatment gaps
• Biomarker testing without actionable guidance leads to suboptimal therapy
• Collaborative evidence generation is essential for cost‑effectiveness validation

Pulse Analysis

Precision medicine promises to tailor treatments to individual genetic profiles, yet the United States health‑care system remains ill‑equipped to fully capitalize on its potential. The AMCP 2026 panel underscored how disjointed insurance coverage, varying state regulations, and siloed data infrastructures create a patchwork that hampers consistent patient access. These systemic fractures not only delay the adoption of cutting‑edge diagnostics but also inflate administrative overhead, eroding the cost‑benefit narrative that innovators need to persuade skeptical stakeholders.

A recurring theme in the discussion was the scarcity of high‑quality, real‑world evidence demonstrating that precision therapies improve survival and lower downstream spending. Payers, especially large commercial insurers and Medicare Advantage plans, demand rigorous cost‑effectiveness analyses before expanding formularies. Collaborative studies that embed payers and providers in the design phase can generate the comparative effectiveness data required to justify premium pricing. Such partnerships also help align incentives, ensuring that reimbursement models reward outcomes rather than volume, a shift essential for sustainable precision‑medicine ecosystems.

Finally, the panel identified clinical decision support (CDS) as the linchpin for translating biomarker results into actionable treatment plans. Embedding CDS directly into electronic health records enables providers to receive real‑time guidance, reducing the lag between test results and therapy selection. As the volume of genomic tests grows, automated alerts and treatment pathways will be critical to prevent missed opportunities and to standardize care across diverse practice settings. Investing in interoperable CDS platforms, coupled with continuous clinician education, will likely accelerate adoption and ultimately deliver the promised improvements in patient outcomes and health‑system efficiency.